^
Association details:
Biomarker:CCNE1 amplification
Cancer:Breast Cancer
Drug Class:CDK2 inhibitor
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Title:

Functional characterization of the 19q12 amplicon in grade III breast cancers

Published date:
03/20/2012
Excerpt:
We investigated the presence of 19q12 amplification in a series of 313 frozen primary breast cancers and 56 breast cancer cell lines using microarray comparative genomic hybridisation (aCGH)...cancer cells harbouring CCNE1 gene amplification are sensitive to CDK2 inhibitors provides a rationale for the testing of these chemical inhibitors in a subgroup of patients with ER-negative grade III breast cancers.
DOI:
10.1186/bcr3154